Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors

Slides:

Advertisements

Similar presentations

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

Advertisements

Laura J. Van ‘t Veer Helen Diller Family Comprehensive Cancer Center University of California, San Francisco Biology of disease Who is at risk for what.

Introduction Integrative Analysis of Genomic Variants in Carcinogenesis Syed Haider, Arek Kasprzyk, Pietro Lio Artificial Intelligence and Computational.

Genomic signatures to guide the use of chemotherapeutics Authors: Anil Potti et. al Presenter: Jong Cheol Jeong.

Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.

Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.

MammaPrint, the story of the 70-gene profile

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

Molecular Biomarkers in Radiotherapy of Cervical Cancer A collaboration project between Department of Gynecologic Oncology and Department of Radiation.

Tang G et al. Proc SABCS 2010;Abstract S4-9.

ERCC 1 isoform expression and DNA repair in NSCLC

High-density lipoprotein and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory.

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

1.DATABASE construction  n=1,715  Median OS=40.0 months, age: 64+/-10 yrs  Histology (adeno/squamous/large): 50% / 45% / 5%  Stage 1/2/3/4: 63% / 27%

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,

Prediction of Glioblastoma Multiforme Patient Time to Recurrence Using MR Image Features and Gene Expression Nicolasjilwan, M.1·Clifford, R.2·Flanders,

Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.

Validation of four gene-expression risk scores in a large colon cancer cohort and contribution to an improved prognostic method Antonio F. Di Narzo 1,

COMPUTATIONAL ANALYSIS OF MULTILEVEL OMICS DATA FOR THE ELUCIDATION OF MOLECULAR MECHANISMS OF CANCER Presented by Azeez Ayomide Fatai Supervisor: Junaid.

Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.

THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.

A comparative study of survival models for breast cancer prognostication based on microarray data: a single gene beat them all? B. Haibe-Kains, C. Desmedt,

Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.

Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.

CBioPortal Web resource for exploring, visualizing, and analyzing multidimentional cancer genomics data.

Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology

Discussant Slides: Title: Radiosensitivity Index Shows Promise for Predicting Outcomes with Adjuvant Radiation in Resected Pancreatic Cancer Patients Poster.

Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,

Kelci J. Miclaus, PhD Advanced Analytics R&D Manager JMP Life Sciences

San Antonio Breast Cancer Symposium – December 6-10, 2016

Advances in Personalized Medicine in Oncology: A Refresher for the Practicing Radiation Therapist Sophia Lamey

MCW Regional Cancer Therapy Program

Hallett, et al., - Supplementary Figure 1

Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced.

Knowledge l Action l Impact

High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.

Exome-Wide Association Study Identifies Low-Frequency Coding Variants in 2p23.2 and 7p11.2 Associated with Survival of Non–Small Cell Lung Cancer Patients

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer Gen Wang, Xiaosong.

Prognostic significance of DDB2 in ovarian cancer.

Volume 17, Issue 1, Pages (January 2010)

Jesper B. Andersen, Snorri S. Thorgeirsson Gastroenterology

Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs McDermott Niamh , Meunier Armelle , Wong Simon , Buchete.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Learning More from Microarrays: Insights from Modules and Networks

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Class Prediction Based on Gene Expression Data Issues in the Design and Analysis of Microarray Experiments Michael D. Radmacher, Ph.D. Biometric Research.

Implementing Genome-Driven Oncology

Volume 5, Issue 6, Pages e3 (December 2017)

Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer Meng Zhou, Long Hu, Zicheng.

Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma Kaushala Jayawardana, Sarah-Jane Schramm,

P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients Matthias Kappler, Johanna Kotrba, Tom Kaune, Matthias Bache,

Molecular prognostication of liver cancer: End of the beginning

Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer Yang et al Presented by Yves A. Lussier MD PhD The University.

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study by Sarah Wagner, Jayakumar Vadakekolathu, Sarah.

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller, MD, PhD. Director, Josep Carreras Leukaemia Research.

Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

PD-L1 is expressed in breast cancer.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

Defining the eTME genes.

Global analysis of the chemical–genetic interaction map.

Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.

Asociación entre el ARNm de PD1 y la respuesta a tratamiento con anti-PD1 en monoterapia en múltiples tipos de cánceres Tomás Pascual*, Laia Paré*, Elia.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Jin MENG Shen FU 57090 (DPD 08) Biology 2 - Head/Neck and CNS Tumors Validation of a radiosensitivity gene signature in radiotherapy-treated patients from The Cancer Genome Altas (TCGA) Jin MENG Shen FU 57090 (DPD 08) Biology 2 - Head/Neck and CNS Tumors

Background Identification of 31 radiosensitivity genes in NCI-60 cell line BMC Genomics 13, 348 (2012)

Workflow Validation of radiosensitivity gene signature in RT-treated patients mRNA profiling expression of 16 different cancer types from TCGA Exclude cancer types without RT or survival information GBM (n=463) HNSCC(n=92) LGG(n=151) Clinical characteristics Kaplan-Meier curves Multivariate Cox regression analysis Comparison between RS and RR patients

Results a b P<0.001 P=0.004 c Tumor classification by radiosensitivity gene signature shows distinct prognostic outcomes of (a)GBM patients(n=463) (b)HNSCC patients(n=92) (c)LGG patients(n=151) P=0.128

Take home messages Our study demonstrates the potential prognostic values of radiosensitivity gene signature identified by Kim et al. The gene signature is a predictive biomarker for radiotherapy treatment benefit for GBM and HNSCC patients. Future prospective studies will be needed to fully refine the integrated prognostic algorithm in clinical radiation oncology.

Thanks